ANVS Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 9.8%, SMA50 -9.47%, SMA200 2.4%). The stock’s 14-day RSI is 52.54 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.27% below its high and over 151.35% above its low. Average 10-day trading volume of 530.08 thousand shares is slightly above the 3-month average of 430.84 thousand, indicating heightened recent market interest.

Annovis Bio, Inc. (NYSE:ANVS) closed at $2.37 USD, losing -$0.13 (-5.20%) from the previous close of $2.50. The stock is currently mid-range between its 52-week high and low $1.11 and $5.50. With a market capitalization of about $46.63 million, Annovis Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.31). Key stats such as the average daily volume over the past year has been around 427.34 thousand shares, in line with its 52-week average. Headquartered in Malvern, PA, Annovis Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Maria L. Maccecchini, the company employs approximately 8 people and listed since January 29, 2020. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.

Annovis Bio, Inc. has 28.36 million shares outstanding. The public float is 24.26 million shares, elevated short interest at 10.86% of float. This equals 2.78 million shares. The short ratio is 8.56 days. Institutional investors hold 13.62% of the float. Insiders own 15.45%. Hoffman Michael B holds 2.56 million shares, Maccecchini Maria-Luisa has 1.21 million shares and White Mark K. has 56.18 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Annovis Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.86. This means the shares are trading above this model’s fair value.

Annovis Bio, Inc. generated EPS of -$1.48 over the past year. Five-year average earnings growth is -73.95%. Wall Street analysts project EPS growth of 18.51% annually over the next five years. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.31. Next year's EPS is expected at $31.86. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $10.00. The high target offers 617.3% upside. The low target suggests 321.94% downside. The mean target is $13.50. This offers 469.62% upside. Annovis Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 2.78%. The prior quarter beat by -11.11%. Over the last six quarters, Apple has recorded several small beats. These include -37.14% in August 14, 2024.

Annovis Bio, Inc. trades at a P/E ratio of -2.08, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.06, also below market averages.

Our AI price prediction model suggests that Annovis Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.95%, with price expected at $2.44 by April 07, 2026, within a range of $2.27 to $2.59 3-Month Outlook: Projected rise of 49.37%, reaching $3.54 by June 22, 2026, with a range of $2.62 to $3.89. 1-Year Outlook: Projected gain of 172.57%, with price at $6.46 by March 24, 2027, within a range of $0.84 to $8.15.

Annovis Bio, Inc. (NYSE:ANVS) shares are down -19.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Annovis Bio, Inc. trading at a premium to the broader market with a P/E of -2.08. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.59, suggesting 1528.27% upside. Our AI forecast model points to short-term strength (2.95% over two weeks), a medium-term rise (49.37% over three months), and a longer-term gain (172.57% over one year), with expected trading ranges indicating moderate volatility.